Compound: zolpidem
SMILES: O=C(N(C)C)Cc1n2c(ccc(c2)C)nc1-c3ccc(C)cc3
InChIKey: ZAFYATHCZYHLPB-UHFFFAOYSA-N
Synonyms: zolpidem, 82626-48-0, Zolpidemum, Sanval, Zolpidem civ, N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide, DTXSID7045946, N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, 7K383OQI23, DTXCID5025946, CHEBI:10125, Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide, Edlular, Zolpi Lich, N,N-dimethyl-2-(6-methyl-2-(4-methylphenyl)imidazo(1,2-a)pyridin-3-yl)acetamide, RefChem:6366, SL-800750-23-N, N05CF02, SL 800750 23 N, 617-367-3, Ambien, CHEMBL911, SL 80-0750, Zolpidem (INN), Zolpidemum [Latin], NCGC00095179-01, N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide, ZOLPIDEM [INN], SL-800750, Zolpidem [INN:BAN], Zolpidem (1.0 mg/mL in Methanol), [3H]zolpidem, CAS-82626-48-0, zolpidem Ambien, UNII-7K383OQI23, Sanval (TN), SL800750, SL 800750, ZOLPIDEM [MI], ZOLPIDEM [VANDF], ZOLPIDEM [WHO-DD], SCHEMBL80516, BSPBio_002278, BIDD:GT0785, SPECTRUM1505369, ZOLPIDEM CIV [USP-RS], GTPL4348, GTPL4362, BDBM26266, GLXC-06071, HMS1922F22, JNB60590, Tox21_111471, STK627113, Zolpidem, >=98% (HPLC), solid, AKOS005560130, Tox21_111471_1, CCG-213403, CS-1468, DB00425, ID57819, NCGC00095179-02, NCGC00095179-03, NCGC00095179-04, NCGC00095179-05, AS-35386, HY-17441, NS00010401, C07219, D08690, AB00698471-07, AB00698471_09, Q218842, SR-01000763006, SR-01000763006-3, BRD-K44876623-001-01-1, BRD-K44876623-001-03-7, N,N,6-Trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide, N,N,6-TRIMETHYL-2-P-TOLYL-IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE, 6-methyl-N,N-dimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide, N,N,6-Trimethyl-2-(4-Methyl Phenyl) Imidazo [1,2-alpha] Pyridine-3-Acetamide, N,N-dimethyl-2-[(4S)-6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide, N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide #, N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[3,2-a]pyridin-3-yl]acetamide, N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide; N,N,6-Trimethyl-2-p-tolylimidazol[1,2-a]pyridine-3-acetamide; SL 80-0750; SL 800750;
Theoretical properties:
molecular_formula: C19H21N3O
molecular_weight: 307.4 g/mol
exact_mass: 307.168462302 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 3
heavy_atom_count: 23
topological_polar_surface_area: 37.6 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 193-197
Descriptions:
{"pubchem": "Zolpidem is an imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. It has a role as a central nervous system depressant, a sedative and a GABA agonist.", "chebi": "An imidazo[1,2-<em>a</em>]pyridine compound having a 4-tolyl group at the 2-position, an <em>N</em>,<em>N</em>-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.", "chembl": "ZOLPIDEM is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Zolpidem, sold under the brand name Ambien among others, is a medication primarily used for the short-term treatment of sleeping problems. Guidelines recommend that it be used only after cognitive behavioral therapy for insomnia and after behavioral changes, such as sleep hygiene, have been tried. It decreases the time to sleep onset by about fifteen minutes and at larger doses helps people stay asleep longer. It is taken by mouth and is available as conventional tablets, extended-release tablets, or sublingual tablets.\nCommon side effects include daytime sleepiness, headache, nausea, and diarrhea. More severe side effects include memory problems and hallucinations. While flumazenil, a GABAA receptor antagonist, can reverse zolpidem's effects, usually supportive care is all that is recommended in overdose.\nZolpidem is a nonbenzodiazepine, or Z-drug, which acts as a sedative and hypnotic as a positive allosteric modulator at the GABAA receptor. It is an imidazopyridine and increases GABA effects in the central nervous system by binding to GABAA receptors at the same location as benzodiazepines. It generally has a half-life of two to three hours. This, however, is increased in those with liver problems.\nZolpidem was approved for medical use in the United States in 1992. It became available as a generic medication in 2007. Zolpidem is a schedule IV controlled substance in the US under the Controlled Substances Act of 1970 (CSA). In 2023, it was the 54th most commonly prescribed medication in the United States, with more than 11 million prescriptions."}